Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab - PubMed
a day ago
- #infection-risk
- #teclistamab
- #RRMM
- Immunoglobulin supplementation (IVIG) reduces both severe and all-grade infections in RRMM patients treated with teclistamab.
- Longer dosing intervals (bimonthly vs. weekly) significantly lower infection rates for severe and all-grade infections.
- Older age and higher beta-2-microglobulin levels increase the risk of severe breakthrough infections during IVIG treatment.
- The study highlights the importance of assessing annualized infection rates to understand the infectious burden in BCMA-directed BsAb-treated patients.